Mylan Pharmaceuticals has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to venlafaxine HCl ER capsules in 37.5-, 75- and 150-mg strengths. The product is the generic version of Wyeth's Effexor XR capsules, a treatment for major depressive disorder. Mylan will be granted a non-exclusive license to the relevant patents that would permit it to launch the capsules in the U.S. on or after June 1, 2011--or earlier in limited circumstances. Additional details of the agreement remain confidential. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/mylan-announces-settlement-agreement-related-antidepressant-effexor-xr